Search Results
Jan 12, 2026, 11:00 ET TYBR Health Appoints Jeff Tyber to Board of Directors
"We are thrilled to welcome Jeff Tyber to our Board of Directors at this pivotal moment in TYBR Health's growth trajectory," said Tim Keane, PhD, Co-founder & CEO of TYBR Health. "Jeff brings to our board an exceptional track record of starting, building and scaling innovative medical device
More news about: TYBR Health
Jan 12, 2026, 10:40 ET AMERICAN SKIN ASSOCIATION APPOINTS NEW BOARD MEMBER STEVEN A. ROSENBERG, MD, PHD
Jan. 12, 2026 /PRNewswire/ -- American Skin Association (ASA) is pleased to announce that Steven A. Rosenberg, MD, PhD, a pioneering figure in cancer immunotherapy, was appointed as the newest member of its distinguished Board of Directors. Dr. Rosenberg will bring his
More news about: American Skin Association
Jan 12, 2026, 09:45 ET IndyGeneUS Bio Files Patent for Clinico-Genomic Insight Engine™, Advancing their AI×Bio Factory Hub from Baltimore to Africa
former FDA regulator is supported by a multidisciplinary founding team of fellow Howard University alumni where Henriques is currently pursuing a PhD in Interdisciplinary Biomedical Sciences (IBMS).Recently, IndyGeneUS Bio entered into an exclusive commercialization agreement with a large contract
More news about: IndyGeneUS Bio
Jan 12, 2026, 09:15 ET Lung Cancer Research Foundation Announces 2026 Requests for Proposals
survival."The opening of LCRF's Requests for Proposals marks the beginning of a new year and brings with it a renewed sense of hope," says Kathryn O'Donnell, PhD, Chair of LCRF's Scientific Advisory Board, Associate Professor, Molecular Biology at UT Southwestern Medical Center. "Each year, we receive proposals
More news about: Lung Cancer Research Foundation
Jan 12, 2026, 09:11 ET 10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease
The study will be led by investigators Kevin Wei, MD, PhD, Jeffrey Sparks, MD, MMSc, Deepak Rao, MD, PhD, Paul Hoover, MD, PhD and Abigail Schiff, MD, PhD, all from the Division of Rheumatology, Inflammation and Immunity at Brigham and Women's Hospital, founding
More news about: 10x Genomics, Inc.
Jan 12, 2026, 09:03 ET LabCentral Names Kamran Tavangar Head of Science Strategy
he was co-founder and COO of Affinivax (vaccines), and CEO of Atias Pharma (therapeutics). Kamran holds an MBA from MIT Sloan School of Management, a PhD in Physiology from Stanford University, and an AB in Molecular Biology from the University of California, Berkeley."I have always been impressed
More news about: LabCentral
Jan 12, 2026, 09:00 ET Debut Appoints Derek Wanner as Chief Commercial Officer Amid Rapid Growth of Its Formulation Business
in beauty."Derek brings a rare combination of commercial rigor, formulation expertise, and deep industry relationships," said Joshua Britton, PhD, Founder and CEO of Debut. "As demand grows for high-performance, science-backed products, his leadership will be instrumental in continuing to scale
More news about: Debut Biotechnology
Jan 12, 2026, 09:00 ET Allos Raises $5M to Apply Causal AI Across Complex Drug Reformulation
pharmaceutical system has treated approval as the finish line, even though for patients it marks the start of a much longer journey," said Aditya Iyer, PhD, CEO and co-founder of Allos AI. "What's been missing is a practical way to keep improving medicines after they reach the market, without relying on
More news about: Allos
Jan 12, 2026, 08:32 ET NYU Langone Health's Perlmutter Cancer Center Announces Upcoming Launch of Molecular Profiling Protocols to Monitor Cancer Treatments
types of cancer across all locations, including on Long Island and in Brooklyn.Led by physician-scientists Shridar Ganesan, MD, PhD, and Kwok-Kin Wong, MD, PhD, the initiative seeks to transform how cancer is assessed, monitored, and treated. Dr. Ganesan, a medical oncologist, Professor of Medicine
More news about: NYU Langone Health
Jan 12, 2026, 08:30 ET Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease
granted the generic name of Garutadustat by the United States Adopted Names (USAN) Council. Garutadustat (originally ISM5411) is a novel, gut-restricted PHD inhibitor developed with Pharma.AI, Insilico's generative platform, for the treatment of Inflammatory Bowel Disease (IBD). Named Barrier Enhancement
More news about: Insilico Medicine
Jan 12, 2026, 08:30 ET Operationalizing ADC Clinical Trials: Best Practices for Success, Upcoming Webinar Hosted by Xtalks
Premier Research, Ashley Herrick, PhD, Vice President, Oncology Program Strategy; and Jordan Curry, Senior Project Director, Oncology, for the live webinar on Thursday, January 29, 2026,
More news about: Xtalks
Jan 12, 2026, 08:30 ET Using Recombinant Insulin and Trypsin for Safer Vaccine Production, Upcoming Webinar Hosted by Xtalks
Novo Nordisk Pharmatech A/S, Sara Bursomanno, PhD, Senior Global Product Manager; and Chantale Julien, MSc, Global Product Manager, for the live webinar on Thursday, January 29, 2026, at 10am EST (4pm
More news about: Xtalks
Jan 12, 2026, 08:00 ET Invictus Therapeutics and Breakthrough T1D Announce Collaboration to Support First-in-Human Trial of Next-Generation Insulin Analog
insulins can help enable automated insulin delivery systems that achieve superior clinical outcomes with minimal user engagement," said Amin Ghavami-Nejad, PhD, Senior Scientist at Breakthrough T1D. "This novel ultra-rapid insulin has the potential to improve both glucose control and quality of life for people
More news about: Invictus Therapeutics, LLC
Jan 12, 2026, 08:00 ET Caris Life Sciences Partners with Everlywell to Launch Caris' Forthcoming MCED Assay, Caris Detect
David Spetzler, MS, PhD, MBA. "By combining our advanced precision medicine technologies with Everlywell's consumer-focused platform, we're creating a powerful new pathway for
More news about: Caris Life Sciences
Jan 12, 2026, 08:00 ET Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
durability data, expanding payer access, and strong engagement across major medical centers and community practices nationwide," said Helen Sabzevari, PhD, President and CEO of Precigen. "We are seeing tremendous enthusiasm from physicians across the country who are eager to bring this therapy to their
More news about: Precigen, Inc.
Jan 12, 2026, 07:03 ET SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat Alzheimer's Disease
continue its development, given their preeminent capabilities and commitment to next generation therapies for neurodegenerative diseases," said Min Li, PhD, Founder and CEO of SciNeuro. "This collaboration delivers an optimal synergy, combining our expertise in disease biology and early development with
More news about: SciNeuro Pharmaceuticals
Jan 12, 2026, 07:00 ET CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update
[email protected] Investor Relations Contact:Aman Patel, CFA & Adanna G. Alexander, PhDICR [email protected]
More news about: Cytosorbents Corp
Jan 11, 2026, 23:52 ET Architects of Progress: Celebrating India's Most Influential Knowledge Leaders
Girls' High School and Moirang College. She earned her BSc and MSc in Nursing (Medical-Surgical) from Dr. MGR University, Chennai, later completing her PhD in Nursing from the Indian Management Academy and a Master's in Hospital Administration from Manipal University. Currently, she is serving as a Principal
More news about: Kiteskraft Productions LLP
Jan 09, 2026, 10:30 ET ENA Foundation Announces 2026 Board of Trustees
Affinity HealthcareENA President Dustin Bass, DNP, MHA, RN, CEN, NEA-BC, of North CarolinaENA Immediate Past President Ryan Oglesby, PhD, MHA, RN, CEN, CFRN, NEA-BC, of FloridaAbout the Emergency Nurses AssociationThe Emergency Nurses Association is the premier professional
More news about: Emergency Nurses Association
Jan 09, 2026, 02:59 ET INFIFORCE's Isabella Bai at CES 2026: China is Moving from Manufacturing to Defining Next-Gen Embodied Intelligence
Shenzhen and Beijing, the company brings together executives from Global 500 firms and a top-tier scientific team, with over 75 percent holding master's or PhD degrees.As of now, INFIFORCE has accumulated more than 35 invention and utility model patents, along with 20 software copyrights. Additionally,
More news about: INFIFORCE
Jan 08, 2026, 16:00 ET CREATE Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
demonstrating best-in-class B cell depletion with in vivo CAR-T in non-human primates leveraging CREATE's proprietary de-risked platform," said Daniel Getts, PhD, CEO and co-founder of CREATE. "These data highlight the clinical maturity of our platform and reinforce its ability to safely and repeatedly program
More news about: CREATE Medicines, Inc.
Jan 08, 2026, 14:41 ET New Dietary Guidelines Emphasize Protein and Recommend Eggs as a High-Quality, Nutritious Choice for Americans at Every Age
priority."Science Continues to Build on Benefits of Eggs"The science behind eggs has been consistent for years," said Jen Houchins, PhD, RD, director of nutrition research at the American Egg Board. "Eggs deliver a complete and bioavailable protein along with essential nutrients like
More news about: American Egg Board
Jan 08, 2026, 13:31 ET Akadeum Life Sciences to Highlight How Microbubbles Enable Rapid Cell Therapy Manufacturing for Larger Patient Populations at Biotech Showcase 2026
Akadeum Life Sciences, the leader in buoyant microbubble cell separation, today announced that its Chief Executive Officer Brandon McNaughton, PhD, will present at
More news about: Akadeum Life Sciences
Jan 08, 2026, 12:11 ET ELEPHAS BIOSCIENCES STRENGTHENS SCIENTIFIC AND CLINICAL LEADERSHIP AS COMPANY ADVANCES TOWARD COMMERCIAL AVAILABILITY OF ITS LIVE-TUMOR IMMUNOLOGY PLATFORM
Premal H. Patel, MD, PhD, appointed Chief Medical Officer; Dr. Michael F. Giordano joins Scientific Advisory BoardMADISON, Wis., Jan. 8, 2026 /PRNewswire/ -- Elephas Biosciences Corporation (Elephas),
More news about: Elephas
Jan 08, 2026, 12:00 ET The Board of Medicine Launches Membership Program Expanding Access to Emerging Medical Knowledge
patients' rights to access the most effective treatments available, even when conventional regulatory frameworks lag behind," said Dr. Dave Rabin, MD, PhD, board-certified psychiatrist, neuroscientist, and Executive Director of The Board of Medicine. "Our members can access cutting-edge research, advanced
More news about: The Board of Medicine